TKS-HPC Today
How Skin Biomarkers Redefine Efficacy Claims and their Scientific Substantiation
Anne Charpentier
Founder & CEO Skinobs
Summary :
The dermo-cosmetic industry is undergoing a paradigm shift toward a predictive, data-driven ecosystem where objective quantification supersedes generic claims. This evolution centers on the systematic integration of cutaneous biomarkers, molecular, proteomic, and lipidomic, measured via non-invasive modalities. While historical assessments are relied on in vitro models, modern breakthroughs utilize adhesive tape-stripping, swabbing, and microfluidic extraction of dermal interstitial fluid (dISF). Synergized with high-throughput “omics” platforms and AI, these techniques enable precise detection of functional markers and microbiota profiles. This convergence facilitates hyper-personalized skincare, bridging laboratory precision with real-world applications to position skin as a vital diagnostic interface for holistic health.
Keywords: Cutaneous Biomarkers, Omics, Non-invasive Sampling, Dermal Interstitial Fluid, AI Diagnostics, Exposome, Personalized Dermocosmetics.
CES 2026 confirms a major evolution: beauty is no longer merely a matter of cosmetics, but is becoming an intelligent technological ecosystem at the crossroads of health, data, and well-being. Artificial intelligence, skin sensors, biological analysis, and connected devices are profoundly transforming the manner in which the skin is observed, analyzed, and treated. This convergence marks the entry of beauty into an era of advanced personalization, founded upon objective measurement and anticipation.
At the heart of this revolution, skin analysis is becoming increasingly granular and continuous. Platforms developed by Korean brands and high-ranking research institutes illustrate this trend by combining ultra-thin electronic patches, environmental sensors, and AI. By measuring real-time UV exposure, humidity, temperature, and even skin micro-deformations, these technologies enable the modeling of the cutaneous “exposome” and the anticipation of its progression.
The analysis of cutaneous biomarkers has become a strategic pillar for brands and CROs, enabling the objectification of product efficacy and the advancement of hyper-personalization. By 2026, the convergence of innovative sampling, high-tech platforms, and AI is redefining cosmetic evaluation. Driven by digitalization, the industry addresses a growing demand for evidence-based skincare. Today’s data-savvy consumers require bespoke solutions precisely calibrated to their unique biological profiles, lifestyles, and environmental exposomes.
Fundamental to this paradigm shift is the systematic integration of cutaneous biomarkers—spanning molecular, proteomic, lipidomic, and biophysical indicators, which offer profound mechanistic insights into hydration kinetics, epidermal barrier integrity, inflammatory cascades, oxidative stress, and the taxonomic composition of the microbiota. Historically restricted to isolated cellular assays or 3D reconstructed human skin models (RhE), these physiological markers are now quantifiable through sophisticated, non-invasive sampling modalities, such as adhesive tape-stripping, swabbing, and the extraction of dermal interstitial fluid (dISF). A company present at the upcoming Cosmetotest Symposium will present its sampling technology based on hollow microneedles for sampling of dermal interstitial fluid (dISF). Access to endogenous and exogenous biomolecules in dISF represents a unique opportunity for the analysis of vital markers, health conditions, and for research into skin biomechanisms.
When synergized with high-throughput ‘omics’ platforms, these methodologies bridge the gap between laboratory-grade analytical precision and real-world, consumer-centric applications, facilitating a new era of evidence-based dermocosmetic innovation.
The transition from in vitro assessment conducted on skin models or 3D organoid cell cultures, to non-invasive in vivo evaluation represents the technological breakthrough achieved in recent years. Latest-generation omics analytical methods enable the extraction of high-quality biological information from samples harvested at the skin surface via stripping or swabbing, without compromising the integrity of the cutaneous barrier. Furthermore, these sampling methodologies are currently the subject of various patents.
This article examines the current landscape and prospective potential of biomarker-driven diagnostics within the dermo-cosmetic sector. By evaluating technological, analytical, and methodological innovations, we illustrate how connected, portable, and high-resolution instruments are poised to redefine personalized beauty, shifting cutaneous assessment from qualitative observation toward a predictive and actionable science. In the context of skin biomarkers, one must consider assays that have been traditionally performed for decades, particularly by active ingredient manufacturers. Historically, these evaluations were predominantly conducted in vitro on epidermal or dermal cell cultures, facilitated by the fact that lipophilic compounds are more readily tested in submerged monocultures, or on 3D reconstructed human skin models (RhE). Modern iterations of these models have gained complexity, now incorporating specialized appendages such as microvascular networks or nociceptive neuronal structures. This evolution was a recurring focal point of scholarly exchange during the poster sessions at the IFSCC 2025 Congress.
In these biomarker-driven assays, three main parameters must be considered:
- The biomarker, a measurable indicator of a cutaneous biological process, is typically a molecule, protein, or enzyme. It may also be a biophysical parameter when measurements are performed directly at the skin surface (impedance, elasticity, color, etc.). Will it be possible in the future to measure volatile organic compounds (VOCs)?
- The analytical substrate has evolved rapidly with swabbing and tape–stripping techniques, whose nature does not interfere with analysis. These, in situ, non-invasive, painless samples enable ultra-personalized results that inform product recommendations. Microfluidic sampling of interstitial fluids may emerge in the future.
- The analytical method is central to expectations, as it must be reliable and rapid. Beyond classical protein assays such as ELISA or Western blot, omics analyses provide miniaturization, reproducibility, and near-real-time measurement.
Skin biomarkers, as true biological signatures, are now powerful tools for personalized cosmetic and dermocosmetics studies. At the IFSCC congress in Cannes, one of the leading cosmetics company presented the Cell–Bioprint, launched in the USA, performing proteomic analyses of three to five proteins to estimate each consumer’s “biological skin age” and provide tailored recommendations.
This revolution in biomarker quantification highlights the diversity of measurable markers, yet a key limitation is that samples predominantly originate from superficial layers. Swabbing collects surface cells, suitable for assessing microbiota, hydration, inflammation, oxidation, and overall barrier function, but precludes evaluation of dermal structural biomarkers. Tape-stripping reaches slightly deeper epidermal layers, while VOC measurements may offer future avenues, though current sensors remain bulky and lab-confined.
Proteomic analysis of stratum corneum samples (e.g., LC-MS/MS) targets keratins (K1, K10, K14…), filaggrin and derivatives (NMF profile), transglutaminases TG1/TG3, cytokines (IL-1α, IL-1RA, IL-8), and oxidized/carbonylated proteins. Proteomics, analogous to genomics for the DNA detection and metabolomics for the metabolites search, reflects functional outcomes: metabolite detection confirms protein activity and effective propagation of DNA-initiated pathways. Rapid lipidomic methods can additionally measure ceramides, cholesterol, fatty acids, and squalene.
Advanced studies on skin models or explants allow hundreds to thousands of biomarkers to be assessed, using platforms such as reconstructed skin augmented with capillaries, neuronal cells, microfluidics, or organ–on–chip devices. These approaches provide a versatile framework for elucidating skin biology, monitoring individual responses, and developing precision dermocosmetics interventions.
Recently, several companies specializing in microbiota analysis have proposed evaluating the activity of a topical product within minutes using skin sampling. Inspired by the speed of antigenic tests, these miniaturized devices can, for instance, measure 25 biological parameters. By combining cutting-edge microbiology and AI, these technologies analyze a complex signature of microbial proteins, such as indicators of diversity and balance for several bacteria (Cutibacterium acnes, Staphylococcus aureus, Staphylococcus epidermidis, Malassezia spp., Corynebacterium…). Some of these diagnostics offer the possibility of establishing a signature of skin sensitivity by detecting inflammation markers and oxidation potential.
Wearable sensors and devices also play a pivotal role in this transformation. Companies are developing advanced optical measurement technologies independent of skin phototype, as well as intelligent patches that analyze sweat to provide continuous insights into the body’s physiological state. These innovations reinforce the concept of beauty connected to holistic health, wherein the skin becomes a data interface in its own right.
Regarding biophysical, connected, and portable measurements for decentralized use, Barlier, Servant, et al. (2024) provided a comprehensive longitudinal study demonstrating that current mobile device parameters increasingly align with standardized laboratory metrics. Future iterations are expected to integrate clinical-grade or socially-driven metrics, reflecting both dermo-cosmetic trends and the influence of digital advocacy. However, significant structural challenges persist, specifically concerning Artificial Intelligence (AI) integration, algorithmic interpretation, and GDPR compliance. Furthermore, addressing ethnicity-related biases is critical; research indicates that diagnostic accuracy can vary by up to 15-20% across different phototypes if algorithms are not trained on diverse datasets. Other hurdles include hardware reliability, connectivity, ergonomics, and long-term robustness.
The future of cosmetic science is defined by two trajectories: the deployment of smartphone-based spectroscopy and the domestic adaptation of medical technologies. These tools utilize probes, patches, or swabbing to facilitate high-throughput omics analysis, while connected mirrors envision holistic integumentary assessments. Within this ecosystem, CROs are vital for providing scientific validation, ensuring devices transcend mere novelty through expert guidance and AI interfaces. Furthermore, neurosensory modalities like EEG complement traditional biomarkers. Collectively, advancements in VOC analysis and microfluidics position real-time skin diagnostics as a proxy for systemic health, revealing previously inaccessible physiological mechanisms.
In conclusion, bringing biomolecules out of the body and into analysis is paramount for the next step in life science. The convergence of technological innovation and advanced biological inquiry is fundamentally restructuring dermo-cosmetic science. By integrating high-throughput proteomic and lipidomic profiling with non-invasive sampling, such as microfluidics, tape-stripping, and spectroscopy, the industry has transitioned from descriptive observation to a mechanistic elucidation of cutaneous biology. These advancements enable real-time, laboratory-grade measurements, facilitating skincare solutions precisely calibrated to an individual’s biological signature and environmental exposome.
Despite this progress, the field remains at a critical inflection point. While superficial sampling effectively quantifies hydration, inflammation, and microbiota balance, capturing deeper dermal structural biomarkers non-invasively persists as a technical challenge. Emerging frontiers, including Volatile Organic Compound (VOC) sensing, organ-on-chip platforms, and neurosensory monitoring, promise to expand this horizon by linking cutaneous changes to systemic physiology.
To ensure these tools transcend mere novelty, rigorous validation by Contract Research Organizations (CROs) and ethical AI-driven interpretation are indispensable. Ultimately, the future of beauty science lies in harmonizing miniaturized, high-resolution analytics with consumer-centric usability. As the biomarker library expands, the skin serves as a definitive diagnostic interface for holistic health, positioning dermo-cosmetics at the vanguard of precision wellness and personalized medicine.
The collective integration of these innovations delineates a singular trajectory: that of predictive, quantifiable, and connected beauty. In this paradigm, beauty emerges as an autonomous field of technological innovation, where scientific precision, user experience, and tangible efficacy supersede generic claims. For brands and consumers alike, this new era facilitates a more intelligent, responsible, and personalized relationship with cutaneous health.
References
Foucher, A., Nouveau, S., Piffaut, V. et al. Clinical vs. chronological skin age: exploring determinants and stratum corneum protein markers of differential skin ageing in 351 healthy women. Sci Rep 14, 23643 (2024). https://doi.org/10.1038/s41598-024-65083-4
Menon GK, Cleary GW, Lane ME. The structure and function of the stratum corneum. Int J Pharm. 2012;435(1):3–9. Epub 2012/06/19. 10.1016/j.ijpharm.2012.06.005 – DOI – PubMed
Raymond AA, Gonzalez de Peredo A, Stella A, Ishida-Yamamoto A, Bouyssie D, Serre G, Monsarrat B, Simon M. Lamellar bodies of human epidermis: proteomics characterization by high throughput mass spectrometry and possible involvement of CLIP-170 in their trafficking/secretion. Mol Cell Proteomics. 2008. November;7(11):2151–75. Epub 2008 Jul 12 10.1074/mcp.M700334-MCP200 – DOI – PubMed
L’Oréal / Cell BioPrint & Longevity : https://www.loreal.com/en/press-release/research-and-innovation/loreal-cell-bioprint/
New testing methods in Beauty, new trends and innovative solutions to evaluate in vivo cos-metics efficacy: a technological panorama of nomad and connected diagnostic devices-Leaticia Leunkeu2, Pascale Barlier1, Anne Charpentier2, Jean-Jacques Servant3-IFSCC CONGRESS 2025
Anne Charpentier
Founder & CEO Skinobs
